Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Globus Medical Inc
(NY:
GMED
)
71.59
+0.05 (+0.07%)
Streaming Delayed Price
Updated: 9:33 AM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Globus Medical Inc
< Previous
1
2
3
4
5
6
7
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Metagenomi and Encourages Investors to Contact the Firm
September 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
While growth is established for NYSE:GMED, the stock's valuation remains reasonable.
September 11, 2024
While growth is established for NYSE:GMED, the stock's valuation remains reasonable.
Via
Chartmill
Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Domino’s and Encourages Investors to Contact the Firm
September 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Looking Into Globus Medical's Recent Short Interest
September 06, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Globus Medical Through 8 Analysts
August 28, 2024
Via
Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Centuri, Medpace, Customers Bancorp, and Globus and Encourages Investors to Contact the Firm
August 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Globus Medical, Inc. (GMED) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
GMED Investors Have Opportunity to Join Globus Medical, Inc. Securities Fraud Investigation with the Schall Law Firm
August 21, 2024
From
The Schall Law Firm
Via
Business Wire
Looking Into Globus Medical's Recent Short Interest
August 19, 2024
Via
Benzinga
What 8 Analyst Ratings Have To Say About Globus Medical
August 07, 2024
Via
Benzinga
Globus Medical Launches ADIRA™ XLIF™ Plate System
August 21, 2024
From
Globus Medical
Via
GlobeNewswire
Investors should take note of NYSE:GMED, a growth stock that remains attractively priced.
August 21, 2024
GLOBUS MEDICAL INC - A (NYSE:GMED) stands out as a growth opportunity that won't break the bank.
Via
Chartmill
GLOBUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Globus Medical, Inc. on Behalf of Globus Stockholders and Encourages Investors to Contact the Firm
August 19, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Globus Medical, Inc. (GMED) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 18, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
NYSE:GMED is showing decent growth, but is still valued reasonably.
July 31, 2024
NYSE:GMED, a growth stock which is not overvalued.
Via
Chartmill
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Globus Medical, Inc. (GMED)
August 16, 2024
From
Kirby McInerney LLP
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
August 16, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
August 15, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Peering Into Globus Medical's Recent Short Interest
July 25, 2024
Via
Benzinga
Where Globus Medical Stands With Analysts
July 15, 2024
Via
Benzinga
NYSE:GMED is not too expensive for the growth it is showing.
June 18, 2024
Looking for growth without the hefty price tag? Consider NYSE:GMED.
Via
Chartmill
The Law Offices of Frank R. Cruz Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
August 15, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
Globus Medical (GMED) Q2 2024 Earnings Call Transcript
August 06, 2024
GMED earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
GMED Stock Earnings: Globus Medical Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
GMED stock results show that Globus Medical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Globus Medical Reports Second Quarter 2024 Results
August 06, 2024
From
Globus Medical
Via
GlobeNewswire
Globus Medical Receives FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System
July 17, 2024
From
Globus Medical
Via
GlobeNewswire
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
July 16, 2024
From
Globus Medical
Via
GlobeNewswire
For those who appreciate growth without the sticker shock, NYSE:GMED is worth considering.
July 09, 2024
GLOBUS MEDICAL INC - A (NYSE:GMED) is showing decent growth, but is still valued reasonably.
Via
Chartmill
Staar Surgical Stock Earns RS Rating Upgrade
June 27, 2024
On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.